Biotech, in brief

Researchers at the University of California, Berkeley gave the drug semaglutide to healthy 20-month-old female mice, an age close to a 60-year-old person. [1][2]

Semaglutide is the medicine sold as Ozempic and Wegovy. It copies a gut hormone that tells the brain you have eaten. [1]

Treated mice had a median lifespan of 834 days. Untreated mice had 742 days, so the gain was about 12%. [1]

The treated mice also did better on tests of coordination, muscle strength and blood sugar after three months. [2][3]

Signs of ageing eased too: less inflammation, and less of the usual loss of the body's power to repair itself. [2][3]

The mice on the drug chose to eat 24% less, which is the obvious explanation for all of it. [1][2]

So the team added a group of untreated mice fed exactly that much and nothing more. [1]

The two groups came out similar on how long they lived, so most of the extra life is the eating less. [1]

But the drugged mice beat the dieting mice on spatial memory, on exploring, and on holding blood sugar steady. [1][2]

Resting metabolic rate, which is how fast a body burns fuel while doing nothing, fell in the dieting mice and stayed roughly level in the drugged ones. [2][3]

The lead author says that points to a second route the drug takes, and that nobody can yet name it. [1][2]

The whole result is in female mice of one inbred laboratory strain, treated for three to five months. No drug is approved anywhere for ageing. [3][4][40]

Why it matters. The next real test is a human trial that measures ageing rather than one disease at a time, and until one reports, every claim here rests on mice.

Three people died after a severe immune reaction in Novartis trials of its cell therapy rap-cel, and Bristol Myers Squibb reported inflammatory events in its own. Shares in Kyverna, Cabaletta, Allogene, CRISPR Therapeutics and Fate fell sharply before recovering. [5]

Why it matters. Analysts have settled on the faster method both firms used to grow the cells as the likely cause, and slower rivals are saying so loudly.

Eli Lilly agreed to pay up to $2.875bn for Merida Biosciences, a Massachusetts startup whose drugs tag and destroy the specific antibodies that attack a patient's own body. It is Lilly's 13th purchase of a smaller biotech this year. [6][7]

Why it matters. Instead of switching the whole immune system down, this removes one misfiring part of it -- and it is obesity money paying for the shift.

Ultragenyx said on 2 September that GTX-102 gave no benefit over a dummy treatment in a large final-stage trial in Angelman syndrome, a rare condition causing severe intellectual disability. Early trials had looked strong. [8]

Why it matters. Families had hoped it would be the first drug to improve thinking and communication in an intellectual disability, and investors had treated it as the firm's route to profit.

Teva said its antibody TEV-408 significantly reduced gluten-caused damage to the gut lining, against a dummy, over eight weeks in a mid-stage trial. The same drug showed early promise in the skin condition vitiligo. [9]

Why it matters. Celiac disease has no approved medicine at all; the only treatment is never eating gluten again.

Tumours shrank in more than 30% of people with the commonest form of lung cancer in a small trial of daraxonrasib, published on 2 September. All had a mutation in the RAS family of proteins and had already tried other treatments. [10]

Why it matters. The US regulator approved the same drug for pancreatic cancer a week ago; some tumours in this trial started growing again, and a larger randomised trial has to report first.

Patients given immune-system cancer drugs earlier in the day lived a median 21.4 months, against 13.1 months for those treated later, in a look back at 2,631 patients at one hospital in Manchester, England. [11]

Why it matters. The senior author says timing alone cannot be blamed -- sicker patients may simply get later slots -- and randomised trials are planned.

Alcon, Astellas, BeOne, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva and UCB agreed to tie their US Medicaid prices to the lowest paid in other countries, in exchange for relief from US import tariffs. [12]

Why it matters. Medicaid already gets steep discounts by law, the terms were not published, and the deals leave out private insurance and the far bigger Medicare programme.

Four US medical societies published joint flu, Covid and RSV vaccine guidance on 2 September. The US disease agency's expert advisory panel was dismissed in 2025 and its replacement is stuck in a court fight. [13][14]

Why it matters. The recommendations largely match the ones in place before, which is the point: the advice did not change, the body giving it did.

Nine cancer drugs approved in the United States in 2024 launched above $400,000 a year, on a count by the Institute for Clinical and Economic Review. One cell therapy is listed at $600,000 for a single infusion. [15]

Why it matters. Twenty years ago even the prospect of a $100,000-a-year cancer drug drew fierce criticism. [15] Analysts now call the newest launch possibly the fastest in the history of cancer medicine. [16]

Researchers built more than 44,000 versions of the virus phi X174, altering nearly every one of its 5,386 DNA letters, and measured what each change did. One of the study's leaders says that even here they cannot explain why a quarter of the mutations kill the virus. [17]

Why it matters. The leading AI tools failed to predict them, in the most exhaustively studied small genome there is.

Reading the protein-coding DNA of 3,964 people with obsessive-compulsive disorder or long-running tic disorders turned up 36 high-confidence risk genes, against four before. [18]

Why it matters. The two conditions affect one to two people in a hundred and have almost nothing aimed at their causes.

Adding the clot drug tirofiban to aspirin did not significantly cut worsening or new strokes in a trial of one narrow stroke type. The bad outcome hit 79 patients on the drug and 89 on the dummy. [19]

Why it matters. Patients whose feeding artery was more than 30% narrowed did appear to gain, which is the kind of hint that needs its own trial rather than a headline.

Adding venetoclax to standard chemotherapy in newly diagnosed double-hit lymphoma killed more patients than it saved: six deaths on treatment out of 37, against one out of 36, and 52% alive at two years against 72%. The cohort was shut early. [20]

Why it matters. The drug is approved and effective elsewhere in blood cancer, which is how a sensible-looking combination gets built.

A CD19 cell therapy grown locally in five hospitals in the Netherlands and Belgium, rather than shipped to a central factory, was tested in 24 people with lymphoma. Four died of treatment-related causes and a dose was chosen for the next stage. [21]

Why it matters. Central manufacturing is what makes these treatments slow and costly, and it is the same production question now hanging over the paused autoimmune trials.

Researchers made more than 100 delivery containers from AI-designed protein assemblies, instead of copying a virus, and used them to move RNA into cells. [22]

Why it matters. Almost every gene therapy today borrows a virus's shell, and inherits the immune reactions that come with it.

A Nature feature on 2 September sets out where six years of long COVID research now stands. One 2024 estimate puts the number affected worldwide at 400 million, at a yearly economic cost near $1 trillion. [23]

Why it matters. It sits alongside older illnesses that follow an infection, which medicine spent decades declining to believe in.

Blood markers of Alzheimer's rose step by step with disease severity in 967 older Nigerian adults, and did so on two different testing platforms. [24]

Why it matters. Nearly all the evidence for these tests comes from wealthy countries, and a test never checked elsewhere has an unknown floor.

Twelve months of estriol and progesterone improved self-reported brain fog, memory and processing speed in a case series of twenty menopausal women, average age 53.5. There was no comparison group. [25]

Why it matters. About 62% of women going through menopause report brain fog, and the evidence base for treating it is close to empty.

Diseases of ageing are the biggest part of the world's disease burden and the largest lifetime burden facing a newborn, even in low-income countries, on an analysis of Global Burden of Disease data. [26]

Why it matters. The authors argue the gains compound: each reduction makes the next one worth more, which is an argument for funding ageing rather than one disease at a time.

Across 25,800 adults in Japan, antibody levels after a third Covid dose fell to about a tenth of their peak by two years. Infection on top of vaccination held levels higher for longer. [27]

Why it matters. Booster schedules are set from data like this, and almost all of it has stopped at one year.

Modelling of six invented respiratory pandemics puts the total loss -- health, money and lost schooling -- between 1.9% and 439% of a country's yearly output, depending on the disease and the country's income. [28]

Why it matters. Closures triggered by the outbreak generally beat long fixed school closures, and the spread of that range is the argument for preparing in advance.

A Ugandan non-profit that has protected the mountain gorillas of Bwindi from human diseases since 2003 is moving to AI models that predict outbreaks rather than react to them. [29]

Why it matters. The park's edge is where 120 mammal species, livestock and people meet, and that meeting is where new human diseases usually begin.

An open platform called AdaptiveFlow screened a library of 69 billion buyable drug-like molecules on up to 5.6 million processors, and found strong blockers of two disease targets. [30]

Why it matters. Screening at this size has belonged to a handful of large companies; the code and the library are now public.

A workflow called Mirror-Peptidizer designed mirror-image protein fragments that stick to three cancer and immune targets, without having to chemically build the mirrored target first. [31]

Why it matters. Mirror-image fragments survive the body's protein-chopping enzymes, which is why ordinary ones so often fail as drugs.

Fortrea paid $45m for Worldwide Clinical Trials' early-phase business, including a 200-bed clinic and a laboratory, both in Texas. [32]

Why it matters. The buyer wants fewer handovers between the ward running a first-in-human dose and the laboratory reading its blood samples.

Genprex hired Andelyn Biosciences to scale up manufacturing of a gene therapy delivered into the pancreas through its own duct, meant to turn one kind of pancreatic cell into an insulin-making one. [33]

Why it matters. The programme is aiming at trials rather than in them, and this deal is about being able to make enough of it to try.

An analysis across sixteen countries found that work combining synthetic biology, AI and laboratory robots falls between biosecurity, AI, export-control and data rules, none of which were written for it. The authors say the friction multiplies rather than adds. [34]

Why it matters. A project can be legal in each country separately and impossible between them.

AusperBio raised $120m to push AHB-137, a drug that switches off a hepatitis B protein, through late-stage testing. The trial is running in China. [35]

Why it matters. Chronic hepatitis B infects nearly 296 million people and has no cure, only suppression.

Chemists at Peking University built proteins that stay inactive until they meet nitric oxide, a gas the body releases at sites of inflammation. [36]

Why it matters. A drug that only wakes up where the disease is does not have to be aimed at it.

A framework called MolDockLab tested five docking programs, 15 scoring methods and three ranking strategies against about 200 compounds with known activity, then picked the best combination for that target. [37]

Why it matters. The answer a computer screen gives depends on which tools were chosen, and that choice is usually made by habit.

Four senior US drug and device regulators wrote on 2 September that trials run with few or no American patients are harder to inspect without warning, harder to apply to Americans, and increasingly a worry for lawmakers. [38]

Why it matters. Where a trial is run is turning into a regulatory question rather than only a cost one.

Dean Ariel, a family doctor writing in the journal Nature Aging, says patients now arrive with questions about ageing medicine that clinicians were never trained to answer, and argues the profession should prepare rather than improvise. [39]

Why it matters. Today's mouse result is exactly the kind of finding that produces those questions in a waiting room.